Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Shares Outstanding (2016 - 2025)

Regenxbio has reported Shares Outstanding over the past 12 years, most recently at $50.9 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $50.9 million for Q4 2025, up 2.71% from a year ago — trailing twelve months through Dec 2025 was $50.9 million (up 2.71% YoY), and the annual figure for FY2025 was $50.9 million, up 2.71%.
  • Shares Outstanding for Q4 2025 was $50.9 million at Regenxbio, up from $50.6 million in the prior quarter.
  • Over the last five years, Shares Outstanding for RGNX hit a ceiling of $50.9 million in Q4 2025 and a floor of $42.5 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $43.8 million (2023), compared with a mean of $45.9 million.
  • Biggest five-year swings in Shares Outstanding: increased 14.3% in 2021 and later increased 1.04% in 2023.
  • Regenxbio's Shares Outstanding stood at $42.8 million in 2021, then grew by 1.09% to $43.3 million in 2022, then increased by 1.73% to $44.0 million in 2023, then increased by 12.49% to $49.5 million in 2024, then rose by 2.71% to $50.9 million in 2025.
  • The last three reported values for Shares Outstanding were $50.9 million (Q4 2025), $50.6 million (Q3 2025), and $50.4 million (Q2 2025) per Business Quant data.